CuII(atsm) significantly decreases microglial reactivity in patients with sporadic amyotrophic lateral sclerosis.

Keywords: amyotrophic lateral sclerosis (ALS); clinical trial; copper-ATSM; microglia; sporadic; therapy EN amyotrophic lateral sclerosis (ALS) clinical trial copper-ATSM microglia sporadic therapy 1 2 2 10/31/23 20231001 NES 231001 Dear Prof. T. S. Jacques: The copper compound Cu SP II sp (atsm) (a.k.a. CuATSM) is neuroprotective in diverse mouse models of neurodegenerative disease and has progressed to clinical trials as a novel drug candidate. Amyotrophic lateral sclerosis (ALS), clinical trial, copper-ATSM, microglia, sporadic, therapy. [Extracted from the article]